Price$38.41-2.28 (-5.60%)
02:00 PM07:45 PM
News · 26 weeks45-50%
2026-01-252026-07-19
Mix1990d
- Insider8(42%)
- Other5(26%)
- SEC Filings4(21%)
- Earnings2(11%)
Latest news
25 items- PRSamsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (BYOOVIZ® / AMELIVU®) to reference ranibizumabIn treatment-naïve patients, SB11 provided functional and anatomical improvements, while BCVA and CST were well maintained in patients who were switched from other anti-VEGF treatments to SB11, adding clinical confidence in using SB11 INCHEON, Korea and NASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, presented interim data from a post-marketing surveillance (PMS) study on SB11 (US brand name: BYOOVIZ®, Korea brand
- PRHarrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual MeetingNASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the presentation of three studies supporting IHEEZO® (chloroprocaine HCl ophthalmic gel 3%), a broadly labeled low viscosity ocular anesthetic gel, and BYOOVIZ® (ranibizumab-nuna)i, an FDA-approved biosimilar referencing LUCENTISii (ranibizumab) at the American Society of Retina Specialists (ASRS) 2026 Annual Meeting. Collectively, the presentations expand the growing body of clinical and real-world evidence supporting Harrow's retina portfolio and reinforce Harrow’s commitment to generating quality evidence that strengthe
- PRSamsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with HarrowIn July 2025, Samsung Bioepis entered into partnership with Harrow for commercialization of two interchangeable ophthalmology biosimilars — BYOOVIZ® (ranibizumab-nuna) and OPUVIZ™ (aflibercept-yszy) — in the US BYOOVIZ was the first ophthalmology biosimilar to gain FDA approval in September 2021 BYOOVIZ had been previously commercialized by Biogen since June 2022, until the company returned commercial rights back to Samsung Bioepis at the end of 2025 Samsung Bioepis Co., Ltd. today announced the relaunch of BYOOVIZ® (ranibizumab-nuna) in the United States (US), in partnership with Harrow (NASDAQ:HROW). Harrow became responsible for commercialization of BYOOVIZ® (ranibizumab-nuna),
- INSIDERSEC Form 4 filed by Director Sternberg Perry J.4 - HARROW, INC. (0001360214) (Issuer)
- INSIDERSEC Form 4 filed by Director Graves Adrienne L4 - HARROW, INC. (0001360214) (Issuer)
- INSIDERSEC Form 4 filed by Director Silvernail Lauren P4 - HARROW, INC. (0001360214) (Issuer)
- SECHarrow Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - HARROW, INC. (0001360214) (Filer)
- PRHarrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric EyecareVERKAZIA is now supported by a comprehensive commercial strategy focused on physician education, patient access, and affordability initiatives to ensure dependable supply and remove access barriersVERKAZIA is indicated for the treatment of all forms of vernal keratoconjunctivitis (VKC), a serious allergic eye disease that primarily affects children and may lead to sight-threatening conditions if left untreated or undertreatedVERKAZIA is a calcineurin inhibitor immunomodulator that targets the underlying inflammatory mechanisms of VKC and may reduce the need for steroid rescue, all of which are associated with risks such as glaucoma or cataract formation NASHVILLE, Tenn., June 10, 2026 (GL
- SECHarrow Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - HARROW, INC. (0001360214) (Filer)
- PRHarrow to Present at William Blair's 46th Annual Growth Stock ConferenceNASHVILLE, Tenn., May 27, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present at William Blair's 46th Annual Growth Stock Conference on Wednesday, June 3, 2026, at 8:40 AM CT, in Chicago, IL. The presentation will be webcast live and can be found on the Company's website. A replay will be on the website for approximately 90 days following the event. About HarrowHarrow, Inc. (NASDAQ:HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and ba
- INSIDERDirector Silvernail Lauren P bought $31,000 worth of shares (1,000 units at $31.00) (SEC Form 4)4 - HARROW, INC. (0001360214) (Issuer)
- INSIDERDirector Graves Adrienne L bought $31,070 worth of shares (1,000 units at $31.07) (SEC Form 4)4 - HARROW, INC. (0001360214) (Issuer)
- INSIDERSEC Form 4 filed by CHIEF SCIENTIFIC OFFICER Shojaei Amir4 - HARROW, INC. (0001360214) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Baum Mark L bought $302,000 worth of shares (10,000 units at $30.20), increasing direct ownership by 0.33% to 2,996,130 units (SEC Form 4)4 - HARROW, INC. (0001360214) (Issuer)
- INSIDERPRESIDENT AND CFO Boll Andrew R. bought $104,650 worth of shares (3,500 units at $29.90), increasing direct ownership by 0.43% to 814,679 units (SEC Form 4)4 - HARROW, INC. (0001360214) (Issuer)
- SECSEC Form 10-Q filed by Harrow Inc.10-Q - HARROW, INC. (0001360214) (Filer)
- SECHarrow Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - HARROW, INC. (0001360214) (Filer)
- PRHarrow Announces First Quarter 2026 Financial ResultsFirst Quarter 2026 and Selected Highlights: VEVYE® delivered record new and total prescription performance (despite an approximate 18% decline in the overall branded dry eye category)VEVYE demand growth on track to deliver 2026 revenue of over $100 millionQuarterly revenue of $44.2 million, including a non-recurring gross-to-net revenue adjustment connected to new VEVYE commercial coverage, which lowered Q1 revenue by approximately $8 millionIHEEZO® unit demand increased 18% year-over-year, with 82% of units from retina accountsTRIESENCE® unit demand more than doubled year-over-year, the sixth consecutive quarter of growthSecond Quarter revenue expected between $71 million and $81 millionF
- PRHarrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026NASHVILLE, Tenn., April 27, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the first quarter ended March 31, 2026, on Monday, May 11, 2026, after the market close. The Company will also post its first quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, May 12, 2026, to discuss the results and provide a business update. Conference Call InformationParticipants can access the live webcast of Harrow's presentation on the "Investors
- SECSEC Form DEFA14A filed by Harrow Inc.DEFA14A - HARROW, INC. (0001360214) (Filer)
- SECSEC Form DEF 14A filed by Harrow Inc.DEF 14A - HARROW, INC. (0001360214) (Filer)
- PRHarrow Announces the Issuance of J-Code for IOPIDINE® 1%NASHVILLE, Tenn., April 16, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that IOPIDINE® 1% (apraclonidine hydrochloride ophthalmic solution) has been assigned a permanent J-Code (J2374) by the Centers for Medicare & Medicaid Services (CMS). Effective July 1, 2026, IOPIDINE 1% will be reimbursed when administered in the in-office setting. J-Codes are CMS billing designations that allow physicians to be reimbursed directly for drugs administered in their offices. The assignment of a permanent J-Code removes a longstanding practical barrier to routine use of IOPIDINE 1% for office-based procedur
- PRLogiCare3PL Selected as Distribution Partner by HarrowOLIVE BRANCH, Miss., April 14, 2026 /PRNewswire/ -- LogiCare3PL today announced it has been selected by Harrow, Inc. (NASDAQ:HROW) as a distribution partner for Harrow's portfolio of ophthalmic disease management solutions. Effective February 1, 2026, LogiCare3PL is providing both non-title and 3PL title distribution services, supporting distribution of Harrow's products across the U.S. market. LogiCare3PL was selected for its high-touch service model, proven ability to execute quickly and efficiently, and commitment to building a long-term partnership. These capabilities were e
- SECHarrow Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits8-K - HARROW, INC. (0001360214) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Harrow Inc.SCHEDULE 13G/A - HARROW, INC. (0001360214) (Subject)
HROW FAQ
6 questionsWhat does Harrow Inc. do?
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and Visionology, a membership-based online eye health and medication platform. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary...Where does HROW stock trade?
Harrow Inc. (HROW) is listed on NASDAQ.What sector and industry is HROW in?
Harrow Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about HROW?
Harrow Inc. has had 8 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight on 2025-07-11. Recent price targets range from $1600.00 to $2400.00.What companies are similar to HROW?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare HROW side-by-side with any of them on Quantisnow.How can I track HROW on Quantisnow?
Quantisnow aggregates Harrow Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HROW to receive live email and push alerts on every new disclosure.